Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio is a promising biopharmaceutical company with innovative RNA-editing technology, particularly the potential of its lead candidate, KRRO-121, to treat urea cycle disorders (UCDs) and other diseases. Its recently completed PIPE financing has provided the company with a strong balance sheet and extended operational runway, reducing near-term financial risks. However, delays or failures in clinical trials, particularly with KRRO-121, and future dilution concerns are potential risks for investors to consider.

Bears say

Korro Bio is heavily reliant on its AATD program for revenue, as seen through the lack of significant current or projected income. While their advancements in ASGCT data is noteworthy, Korro's dependence on a single main program poses a high level of risk to investors. This is compounded by the fact that the AATD program is still in early stages, with key decisions and filings not expected until at least 2026.

KRRO has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 9 analysts, KRRO has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.